Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Dataderm: Beyond MIPS, Data-Driven Dermatology Quality, Research, and Advocacy
Description
The speaker emphasized that Dataderm is much more than MIPS reporting: it supports quality improvement, research, advocacy, and data-driven transformation of dermatology care. Dataderm predates MIPS because the specialty needed its own data to tell the story of dermatology, demonstrate value to payers and government, and improve outcomes. The registry now has a new platform that lets members access retrospective and prospective data more easily, understand measure performance, and identify documentation gaps. Seeing one’s own data tends to improve performance, and Dataderm’s measures are designed to be practical and relevant to dermatology rather than burdensome or generic. The talk also highlighted that Dataderm is free to join, with costs mainly tied to optional MIPS reporting, and that broader participation from academic and private practices strengthens the national dataset. Beyond quality reporting, Dataderm data have been used in advocacy, such as proving continued use and importance of UVB therapy when payers challenged coverage. Research use is expanding through a new proposal and review process, with projects on treatment patterns, disparities, and access. A major new effort involves partnering with OM1 and using AI to identify patients with likely but undiagnosed diseases such as generalized pustular psoriasis and hidradenitis suppurativa, aiming to shorten time to diagnosis and uncover patterns like pain, mental health comorbidity, and demographic differences. The speaker closed by encouraging members to join, use the AAD resources, and explore Dataderm for research and quality improvement.
View moreConclusions
- DataDerm is valuable because it improves dermatology care by turning registry data into actionable quality feedback that helps clinicians perform better.
- The registry supports more than MIPS reporting; it also fuels research, advocacy, and specialty-specific quality improvement efforts.
- Seeing and querying their own data helps dermatologists identify gaps in documentation and care, which can lead to better patient outcomes over time.
- Because dermatology lacks many objective biomarkers, standardized data collection and outcome measures are essential for meaningful quality measurement and research.
- DataDerm’s large scale and retrospective-plus-prospective design make it uniquely useful for studying rare diseases, disparities, and real-world treatment patterns.
- The registry can provide evidence for advocacy when payers or policymakers underestimate the value or use of dermatologic services.
- New tools like self-service querying and partnerships with AI/real-world data platforms may help uncover undiagnosed patients and accelerate diagnosis.
- The patient-finder work suggests hidden cases of conditions like hidradenitis suppurativa and generalized pustular psoriasis can be detected earlier using real-world data patterns.
- The hidradenitis suppurativa findings imply underdiagnosis may be influenced by pain, psychiatric comorbidity, gynecology encounters, body habitus, and sex-based differences in presentation.
- The overall trajectory of DataDerm is toward broader data access, better analytics, more research output, and practical quality-improvement support for the dermatology specialty.
- J Am Acad Dermatol. 2024 May;90(5):1002-1005.
- J Cosmet Dermatol. 2020 Dec;19(12):3205-3207.